KD Logo

A Guide To The Risks Of Investing In Omega Therapeutics Inc (OMGA)

As this happened, Raymond James downgraded its Omega Therapeutics Inc [OMGA] rating to a Mkt perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Raymond James’s analysts, who began to cover the stock in mid June with a ‘”an Outperform”‘ rating. H.C. Wainwright started covering the stock on December 08, 2022. It rated OMGA as “a Buy”.

Price Performance Review of OMGA

On Tuesday, Omega Therapeutics Inc [NASDAQ:OMGA] saw its stock fall -68.69% to $0.15. Over the last five days, the stock has lost -69.58%. Omega Therapeutics Inc shares have fallen nearly -79.88% since the year began. Nevertheless, the stocks have fallen -95.48% over the past one year. While a 52-week high of $4.46 was reached on 01/06/25, a 52-week low of $0.44 was recorded on 02/04/25. SMA at 50 days reached $0.7418, while 200 days put it at $1.4481.

Levels Of Support And Resistance For OMGA Stock

The 24-hour chart illustrates a support level at 0.0500. On the upside, there is a resistance level at 0.3385. A further resistance level may holdings at 0.5270. The Relative Strength Index (RSI) on the 14-day chart is 19.91, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1067, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.84%. Stochastics %K at 10.82% indicates the stock is a buying.

How much short interest is there in Omega Therapeutics Inc?

A steep rise in short interest was recorded in Omega Therapeutics Inc stocks on 2024-10-31, growing by 0.75 million shares to a total of 6.36 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 5.61 million shares. There was a rise of 11.83%, which implies that there is a positive sentiment for the stock.

The most recent change occurred on September 23, 2022 when Chardan Capital Markets began covering the stock and recommended ‘”a Buy”‘ rating along with a $12 price target.

Most Popular